Phase 1 Dose Escalation Trial of Ilorasertib, a Dual Aurora/VEGF Receptor Kinase Inhibitor, in Patients With Hematologic Malignancies

BACKGROUND: Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of tyrosine kinases. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Garcia-Manero, Guillermo, Tibes, Raoul, Kadia, Tapan, Kantarjian, Hagop, Arellano, Martha, Knight, Emily A., Xiong, Hao, Qin, Qin, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Albert, Daniel H., Oliver, Brian, McKee, Mark D., Ricker, Justin L., Khoury, Hanna Jean
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5563391/
https://ncbi.nlm.nih.gov/pubmed/25933833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0242-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados